Alainna J. Jamal

Alainna J. Jamal

Auto-generated profile, based on publicly available information

Alainna J. Jamal

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
BIBaweleta Isho
Baweleta Isho
KAKento T. Abe
Kento T. Abe
MZMichelle Zuo
Michelle Zuo
AJAlainna J. Jamal
Alainna J. Jamal
BRBhavisha Rathod
Bhavisha Rathod
AGAnne-Claude Gingras
Anne-Claude Gingras
Saliva is an alternative biofluid to serum for detecting and monitoring IgG to SARS-CoV-2 spike and RBD antigens in COVID-19.

25 June 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AJAlainna J Jamal
Alainna J Jamal
MMMohammad Mozafarihashjin
Mohammad Mozafarihashjin
ECEric Coomes
Eric Coomes
JPJeff Powis
Jeff Powis
ALAngel X Li
Angel X Li
SWSharon Walmsley
Sharon Walmsley
We enrolled 91 consecutive inpatients with COVID-19 at 6 hospitals in Toronto, Canada, and tested 1 nasopharyngeal swab/saliva sample pair from each patient using real-time RT-PCR for severe acute respiratory syndrome coronavirus 2. Sensitivity was 89% for nasopharyngeal swabs and 72% for saliva (P = .02). Difference in sensitivity was greatest for sample pairs collected later in illness.

24 January 2017 in Journal of Occupational Health
Verified
Journal Article
Open access
PDF file
BOBen Ouyang
Ben Ouyang
LLLucy D X Li
Lucy D X Li
JMJoanne Mount
Joanne Mount
AJAlainna J Jamal
Alainna J Jamal
LBLauren Berry
Lauren Berry
RTR W Melissa Tai
R W Melissa Tai
Objectives: This field study aimed to determine the incidence and distribution of needlestick injuries among medical trainees at a community teaching hospital in Toronto, Canada. Methods: The study was performed during the 2013-2015 academic years at Toronto East General Hospital (TEGH), a University of Toronto-affiliated community-teaching hospital during the 2013-2015 academic years. Eight-hundred and forty trainees, including medical students, residents, and post-graduate fellows, were identified and invited via email to participate in an anonymous online fluidsurveys.com survey of 16 qualitative and quantitative questions. Results: Three-hundred and fifty trainees responded (42% response rate). Eighty-eight (25%) respondents reported experiencing at least one injury at TEGH. In total, our survey identified 195 total injuries. Surgical trainees were significantly more likely to incur injuries than non-surgical trainees (IRR = 3.03, 95% CI 1.80-5.10). Orthopaedic surgery trainees had the highest risk of a needlestick injury, being over 12 times more likely to be injured than emergency medicine trainees (IRR = 12.4, 95% CI 2.11-72.32). Only 28 of the 88 most recent needlestick injuries were reported to occupational health. Trainees reported a perception of insignificant risk, lack of resources and support for reporting, and injury stigmatization as reasons for not reporting needlestick injuries. Conclusions: Needlestick injuries were a common underreported risk to medical trainees at TEGH. Future research should investigate strategies to reduce injury and improve reporting among the high-risk and reporting-averse trainees.

4 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BIBaweleta Isho
Baweleta Isho
KAKento T. Abe
Kento T. Abe
MZMichelle Zuo
Michelle Zuo
AJAlainna J. Jamal
Alainna J. Jamal
BRBhavisha Rathod
Bhavisha Rathod
AGAnne-Claude Gingras
Anne-Claude Gingras
While the antibody response to SARS-CoV-2 has been extensively studied in blood, relatively little is known about the mucosal immune response and its relationship to systemic antibody levels. Since SARS-CoV-2 initially replicates in the upper airway, the antibody response in the oral cavity is likely an important parameter that influences the course of infection, but how it correlates to the antibody response in serum is not known. Here, we profile by enzyme linked immunosorbent assays (ELISAs) IgG, IgA and IgM responses to the SARS-CoV-2 spike protein (full length trimer) and its receptor binding domain (RBD) in serum (n=496) and saliva (n=90) of acute and convalescent patients with laboratory-diagnosed COVID-19 ranging from 3–115 days post-symptom onset (PSO), compared to negative controls. Anti-CoV-2 antibody responses were readily detected in serum and saliva, with peak IgG levels attained by 16–30 days PSO. Whereas anti-CoV-2 IgA and IgM antibodies rapidly decayed, IgG antibodies remained relatively stable up to 105 days PSO in both biofluids. In a surrogate neutralization ELISA (snELISA), neutralization activity peaks by 31–45 days PSO and slowly declines, though a clear drop is detected at the last blood draw (105–115 days PSO). Lastly, IgG, IgM and to a lesser extent IgA responses to spike and RBD in the serum positively correlated with matched saliva samples. This study confirms that systemic and mucosal humoral IgG antibodies are maintained in the majority of COVID-19 patients for at least 3 months PSO. Based on their correlation with each other, IgG responses in saliva may serve as a surrogate measure of systemic immunity. One Sentence Summary: In this manuscript, we report evidence for sustained SARS-CoV-2-specific IgG and transient IgA and IgM responses both at the site of infection (mucosae) and systemically in COVID-19 patients over 3 months and suggest that saliva could be used as an alternative biofluid for monitoring IgG to SARS-CoV-2 spike and RBD antigens.

15 March 2014 in Transplantation
Verified
Journal Article
Closed access
AJAlainna J. Jamal
Alainna J. Jamal
SHShahid Husain
Shahid Husain
YLYanhong Li
Yanhong Li
OFOlusegun Famure
Olusegun Famure
SKS. Joseph Kim
S. Joseph Kim
CMV-D+/R- serostatus is the only well-established risk factor for late-onset cytomegalovirus (CMV) infection/disease (i.e., incident CMV infection/disease after cessation of prophylactic antiviral therapy). This study aimed to explore other potential risk factors for late-onset CMV infection/disease in kidney transplant recipients. We conducted a retrospective cohort study of 641 kidney transplant recipients in Toronto, Canada, from January 1, 2003, to December 31, 2010. The cumulative incidence of late-onset CMV infection/disease was assessed using the Kaplan-Meier product-limit method. Potential risk factors for late-onset CMV infection/disease were examined using Cox proportional hazards regression models. Cumulative incidence estimates for CMV infection/disease after prophylaxis cessation in D+/R- versus D+/R+ versus D-/R+ patients were 26.2% versus 7.4% versus 3.1% at 6 months and 30.0% versus 7.7% versus 3.7% at 1 year, respectively. D+/R- serostatus (vs. R+ serostatus) and an estimated glomerular filtration rate of less than 45 mL/min (vs. ≥ 60 mL/min) at prophylaxis cessation were independently associated with late-onset CMV infection/disease (hazard ratio, 4.04 [95% confidence interval, 2.39-6.83]; and hazard ratio, 2.03 [95% confidence interval, 1.07-3.88], respectively). Patients with lower estimated glomerular filtration rate at prophylaxis cessation may be at an increased risk of late-onset CMV infection/disease and should be considered for more intensive CMV viral load monitoring, particularly within the first year after prophylaxis cessation.

1 December 2020 in Journal of Hospital Infection
Verified
Journal Article
Closed access
AJA.J. Jamal
A.J. Jamal
LML.F. Mataseje
L.F. Mataseje
KBK.A. Brown
K.A. Brown
KKK. Katz
K. Katz
JJJ. Johnstone
J. Johnstone
MMM.R. Mulvey
M.R. Mulvey